Dose level	Number enrolled	Number evaluable for toxicity	Number with a DLT	Dose‐limiting toxicity information
Ramucirumab 8 mg/kg on days 1 and 15 and merestinib 80 mg QD (28‐day cycle)	7	7	1	One male patient, aged 47 years, had a DLT of grade 3 proteinuria. The patient received ramucirumab on cycle 1, days 1 and 15 and merestinib from day 1 to 28 as per the recommended dosing schedule for phase Ia. On day 15, the patient experienced grade 2 treatment‐related proteinuria. By day 27, the event worsened to grade 3 proteinuria. On day 29, ramucirumab was permanently discontinued and merestinib dosing was halted for the following 2 weeks. On day 43, merestinib dosing resumed at the same dose level. Grade 3 proteinuria persisted until day 71, after which the severity of the TEAE decreased to grade 1 until merestinib discontinuation on day 85 due to PD.